Welcome to our dedicated page for Bright Minds Biosciences news (Ticker: DRUG), a resource for investors and traders seeking the latest updates and insights on Bright Minds Biosciences stock.
Bright Minds Biosciences Inc (DRUG) delivers innovative therapies for neurological and neuropsychiatric disorders through selective serotonin receptor targeting. This page provides investors and researchers with authoritative updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about drug candidates for refractory epilepsy, treatment-resistant depression, and chronic pain management. Our curated news feed includes earnings reports, partnership agreements, and trial data – all sourced directly from company disclosures.
Key updates cover preclinical advancements, Phase I-III trial outcomes, intellectual property developments, and market expansion efforts. Bookmark this page to monitor progress on next-generation serotonergic compounds designed to address critical unmet medical needs.
For stakeholders tracking CNS therapeutic innovations, this resource offers essential insights into Bright Minds Biosciences' scientific pipeline and corporate strategy. Visit regularly for unfiltered access to material events that may impact clinical and investment decisions.
Bright Minds Biosciences (NASDAQ: DRUG) has expanded its Scientific Advisory Board with five distinguished experts in epilepsy research. The new members include Dennis Dlugos, Jacqueline French, Terrence O'Brien, Jo Sourbron, and Joseph Sullivan, bringing extensive experience in epilepsy drug development and research.
This expansion aligns with the company's clinical focus on developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders. The company is currently conducting a Phase 2 BREAKTHROUGH study of BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
Additionally, Bright Minds has granted stock options to purchase 161,000 common shares at US$35.00 per share and 600 Restricted Stock Units to directors, officers, and consultants. The options have a four-year term with vesting periods.
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in three major healthcare conferences in March 2025.
The company's CEO Ian McDonald and senior management will attend:
- TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 1:10pm ET
- Leerink Partners Global Healthcare Conference in Miami on March 12, 2025 (one-on-one meetings)
- BIO-Europe Spring in Milan from March 17-19, 2025
Live and archived webcasts will be available on the company's investor relations website for 90 days following the events.
Bright Minds Biosciences (NASDAQ: DRUG) has appointed Stephen D. Collins, M.D., Ph.D., as Chief Medical Officer (CMO), effective immediately. Dr. Collins brings extensive experience in drug development and clinical expertise in epilepsy, replacing Mark A. Smith M.D., Ph.D., who will retire as Acting CMO but continue in an advisory role.
The appointment comes as the company advances its BREAKTHROUGH Study, a Phase 2 clinical trial evaluating BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE). Dr. Collins previously served as CEO of Biscayne Neurotherapeutics and Biscayne Pharmaceuticals, which was acquired by Supernus Pharmaceuticals. His track record includes leadership roles at Johnson & Johnson, Abbott Laboratories, and Ovation Pharmaceuticals, where he contributed to the development and approval of multiple anti-convulsant therapies.
Bright Minds Biosciences (NASDAQ: DRUG) announces two presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024. The presentations will showcase data on BMB-101, their novel 5-HT2C agonist.
The first presentation by CSO Jan Torleif Pedersen will discuss Phase I study results on safety, tolerability, and pharmacokinetics of BMB-101. The second presentation by COO Alex Vasilkevich will focus on BMB-101's biased 5-HT2C agonism for epilepsy management. Both poster presentations are scheduled for Saturday, December 7, from 12:00 PM to 2:00 PM at South Hall H, Level 1.
Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) has successfully closed a non-brokered private placement, raising USD$35 million through the issuance of 1,612,902 common shares at USD$21.70 per share. Notable participants include Cormorant Asset Management, RA Capital Management, Perceptive Advisors, and other healthcare investors. The proceeds will fund research and development programs and general working capital. The offering included insider participation from director Jeremy Fryzuk and Cormorant Asset Management, who collectively subscribed for 188,940 shares worth USD$4.1 million.
Bright Minds Biosciences (NASDAQ: DRUG) has announced a renewed collaboration with Firefly Neuroscience (NASDAQ: AIFF) for the analysis of EEG data from the BREAKTHROUGH study, a Phase 2 clinical trial of BMB-101. This open-label trial is evaluating the safety, tolerability, and efficacy of BMB-101, a selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).
The study is designed as a basket clinical trial, targeting enrollment of 20 adult participants aged 18-65. It aims to address rare epilepsy disorders characterized by refractory seizures resistant to current treatments. Bright Minds believes BMB-101 has the potential to be a best-in-class 5-HT2C agonist with broad applicability across 30% of epilepsy patients experiencing drug resistance.
Bright Minds Biosciences (NASDAQ: DRUG) has announced positive preclinical data for its proprietary compound BMB-201, a 5-HT2C/2A mixed agonist. The study, conducted through the National Institute of Health pain screening program, demonstrated that BMB-201 had similar efficacy to morphine in several pain models, including plantar incision and L5/L6 nerve ligation in rats.
Key findings include:
- BMB-201 showed superior reductions in mechanical allodynia and pain-related behaviors compared to morphine in nerve ligation models
- Female rodents experienced significant improvement in pain relief and guarding behavior at higher doses
- The compound's efficacy suggests potential for better pain relief than traditional opioids without associated risks
Bright Minds plans to advance BMB-201 into clinical trials, aiming to position it as a non-opioid alternative for neuropathic pain relief.
At the request of CIRO, Bright Minds Biosciences (CSE: DRUG) (NASDAQ: DRUG) has confirmed that the company's management is unaware of any material changes in its operations that could explain the recent increase in market activity. This statement was made in response to unusual trading patterns observed in the company's stock.
The press release, dated October 15, 2024, serves as a formal declaration to investors and regulatory bodies that Bright Minds has not undergone any significant operational changes that would justify the recent market behavior. This type of announcement is often made to ensure transparency and compliance with stock exchange regulations.
Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for CNS disorders, announces participation in upcoming scientific conferences and partnering events. The company will present at:
- Neuroscience 2024 annual meeting in Chicago, October 5–9
- Therapeutic Development at NINDS Chicago, October 7
- BIO-Europe in Stockholm, November 4-6
- Chicago Biocapital Summit, November 6-7
- AES Annual Meeting 2024 in Los Angeles, December 6-10
Presentations will cover novel 5-HT2A-selective agonists, Phase I study results of BMB-101, and biased 5-HT2C agonism for epilepsy management. The company also granted 70,000 stock options to employees and board members, exercisable at $1.65 per share for five years, subject to vesting periods.
Bright Minds Biosciences (NASDAQ / CSE: DRUG) is hosting a Key Opinion Leader (KOL) event on September 25th, 2024, focusing on their Phase 2 BREAKTHROUGH clinical trial of BMB-101 for drug-resistant epilepsies. The event will feature renowned epilepsy experts Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will discuss unmet needs in epilepsy treatment and the potential of novel therapies.
BMB-101 is the first 5-HT2C agonist in clinical studies designed to target therapeutic pathways without receptor desensitization. The KOL event will provide insights into the evolving landscape of drug-resistant seizures and highlight the scientific innovations driving the trial design. Interested parties can register for the webcast in advance, with a replay available for those unable to attend live.
